Saturday, July 11, 2026

Drug profile · INN

forodesine hydrochloride

forodesine hydrochloride (MUNDESINE) is a purine nucleoside phosphorylase inhibitor.

PMDA: approved
Patents linked 0
Pipeline programs 8
News articles 0
Drug details — forodesine hydrochloride
Class
Route
Patents
0
Programs
8
Data quality
0.78

Quick answer

forodesine hydrochloride (MUNDESINE) is a purine nucleoside phosphorylase inhibitor.

Key facts

INN forodesine hydrochloride
Brand MUNDESINE
Mechanism Purine nucleoside phosphorylase inhibitor
Target Purine nucleoside phosphorylase

Mechanism of action

Purine nucleoside phosphorylase inhibitor

Primary target: Purine nucleoside phosphorylase

Approval history

Authority Status Date
PMDA approved

Pipeline programs

  1. BCX1777-Tio-05-202 Phase 2 · Biocryst · Leukemia
  2. Forodesine 200 mg Phase 2 · Biocryst · Cutaneous T-cell Lymphoma (CTCL),
  3. forodesine HCl Phase 2 · Biocryst · Chronic Lymphocytic Leukemia (CLL)
  4. forodesine hydrochloride Phase 2 · Biocryst · Lymphoma
  5. forodesine hydrochloride (BCX-1777) Phase 2 · Biocryst · Leukemia, T-Cell
  6. forodesine hydrochloride (BCX-1777) Phase 2 · Biocryst · B-cell Acute Lymphoblastic Leukemia
  7. forodesine hydrochloride (BCX-1777) Phase 2 · Biocryst · Leukemia, Lymphocytic, Chronic
  8. forodesine hydrochloride Phase 1 · Biocryst · Cancer

Frequently asked questions

What is forodesine hydrochloride?

forodesine hydrochloride (MUNDESINE) is a purine nucleoside phosphorylase inhibitor.

What is the brand name for forodesine hydrochloride?

MUNDESINE is a marketed brand name for forodesine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.